FDA recall D-0581-2025 · initiated Aug 6, 2025
May cause temporary or medically reversible harm; low probability of serious harm.
CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.